Mavacoxib
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 525604

CAS#: 170569-88-7

Description: Mavacoxib is a veterinary drug used to treat pain and inflammation in dogs with degenerative joint disease. It acts as a COX-2 inhibitor.


Price and Availability

Size
Price

50mg
USD 350
Size
Price

100mg
USD 550
Size
Price

200mg
USD 950

Mavacoxib, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 525604
Name: Mavacoxib
CAS#: 170569-88-7
Chemical Formula: C16H11F4N3O2S
Exact Mass: 385.0508
Molecular Weight: 385.3366
Elemental Analysis: C, 49.87; H, 2.88; F, 19.72; N, 10.91; O, 8.30; S, 8.32


Synonym: PHA-739521; PHA739521; PHA 739521; PHA 739,521; PHA739,521; PHA-739,521; Mavacoxib. trade name Trocoxil.

IUPAC/Chemical Name: 4-(5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide

InChi Key: TTZNQDOUNXBMJV-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H11F4N3O2S/c17-11-3-1-10(2-4-11)14-9-15(16(18,19)20)22-23(14)12-5-7-13(8-6-12)26(21,24)25/h1-9H,(H2,21,24,25)

SMILES Code: O=S(C1=CC=C(N2N=C(C(F)(F)F)C=C2C3=CC=C(F)C=C3)C=C1)(N)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Payne-Johnson M, Becskei C, Chaudhry Y, Stegemann MR. Comparative efficacy and safety of mavacoxib and carprofen in the treatment of canine osteoarthritis. Vet Rec. 2015 Mar 14;176(11):284. doi: 10.1136/vr.102397. Epub 2014 Nov 27. PubMed PMID: 25433056; PubMed Central PMCID: PMC4392193.
2: Lees P, Pelligand L, Elliott J, Toutain PL, Michels G, Stegemann M. Pharmacokinetics, pharmacodynamics, toxicology and therapeutics of mavacoxib in the dog: a review. J Vet Pharmacol Ther. 2015 Feb;38(1):1-14. doi: 10.1111/jvp.12185. Epub 2014 Nov 21. Review. PubMed PMID: 25413929.
3: Pang LY, Argyle SA, Kamida A, Morrison KO, Argyle DJ. The long-acting COX-2 inhibitor mavacoxib (Trocoxil™) has anti-proliferative and pro-apoptotic effects on canine cancer cell lines and cancer stem cells in vitro. BMC Vet Res. 2014 Sep 5;10:184. doi: 10.1186/s12917-014-0184-9. PubMed PMID: 25190452; PubMed Central PMCID: PMC4172958.
4: Walton MB, Cowderoy EC, Wustefeld-Janssens B, Lascelles BD, Innes JF. Mavacoxib and meloxicam for canine osteoarthritis: a randomised clinical comparator trial. Vet Rec. 2014 Sep 20;175(11):280. doi: 10.1136/vr.102435. Epub 2014 May 23. PubMed PMID: 24859353.
5: Cox SR, Liao S, Payne-Johnson M, Zielinski RJ, Stegemann MR. Population pharmacokinetics of mavacoxib in osteoarthritic dogs. J Vet Pharmacol Ther. 2011 Feb;34(1):1-11. doi: 10.1111/j.1365-2885.2010.01183.x. PubMed PMID: 21219337.
6: Cox SR, Lesman SP, Boucher JF, Krautmann MJ, Hummel BD, Savides M, Marsh S, Fielder A, Stegemann MR. The pharmacokinetics of mavacoxib, a long-acting COX-2 inhibitor, in young adult laboratory dogs. J Vet Pharmacol Ther. 2010 Oct;33(5):461-70. doi: 10.1111/j.1365-2885.2010.01165.x. PubMed PMID: 20840390.